Introduction: Hormonal therapy in endometrial cancer (EC) is used for patients who wish to
preserve fertility and for patients with advanced or recurrent disease in a palliative setting …

Background Hormonal therapy (HT) is used commonly in the treatment of advanced
endometrial cancer (EC). However, a 2010 Cochrane Review did not show a survival benefit …

One of the most prevalent potential therapeutic targets for women with endometrioid
endometrial cancer (EC) is the estrogen receptor (ER)/progesterone receptor (PR) pathway …

Endometrial cancer is a heterogeneous disease. Type I cancers are hormonally driven,
typically present with a low grade at an early stage, and are of endometrioid histology …

The “gold standard” treatment for endometrial cancer is completely staged surgery, followed
by radiation or chemotherapy, based on the final pathological surgical stage and …

Hormonal therapy and chemotherapy play a major role in the management of advanced or
recurrent endometrial cancer. Progesterone therapy obtains overall response rates ranging …

The median survival of women with advanced or recurrent endometrial cancer is less than
one year. Only half the women with early stage endometrial cancer and poor prognostic …

Background: Cytotoxic chemotherapy has a limited place in the management of advanced or
recurrent endometrial cancer. Commonly used agents include cisplatin and doxorubicin, but …

Purpose: Treatment for patients with recurrent endometrioid endometrial cancer (EEC) are
limited as paclitaxel is the only second-line chemotherapy with a response rate> 13 …

Background Endometrial cancer is a cancer of the lining of the womb and worldwide is the
seventh most common cancer in women. Treatment with hormones is thought to be …